ReviewThe Journal of clinical and aesthetic dermatology2017
Raising Awareness Among Healthcare Providers about Epidermolysis Bullosa and Advancing Toward a Cure.
Review in The Journal of clinical and aesthetic dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study.Orphanet journal of rare diseases · 2020Trial
- Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).Orphanet journal of rare diseases · 2020Trial
- Article
- Topical Treatments for Rare Genetic Dermatological Diseases: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- "It's like nursing a butterfly-so delicate, difficult, and unpredictable" - challenges of nurses in caring for patients with epidermolysis bullosa: a qualitative study.Orphanet journal of rare diseases · 2025Article
- Parents' perception of challenges of caring of children with Epidermolysis bullosa: a qualitative study.BMC research notes · 2024Article
- Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa.EMBO molecular medicine · 2024Article
- Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa.Current drug targets · 2024Review
- Mapping the burden of severe forms of epidermolysis bullosa - Implications for patient management.JAAD international · 2023Article
- Article
- Dystrophic Epidermolysis Bullosa in a Preschooler in a Middle Eastern Country.Global pediatric health · 2023Article
- The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers.Orphanet journal of rare diseases · 2020Article
- Article
- Dental-craniofacial manifestation and treatment of rare diseases.International journal of oral science · 2019Review
- IntegraDermatology and therapy · 2018Article
- A case of a patient with severe epidermolysis bullosa surviving to adulthood.International journal of general medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
28670357PMC5479476W2762496674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.